Qin, Meng

Education background:

2003-2007, Undergraduate of West China School of Pharmacy, Sichuan University
2007-2010, Postgraduate of the Institute of Medicinal Plant Development (IMPLAD) , Peking Union Medical College

Work experience :

2013-2015, Postdoctoral fellow of Biopharmagen Corp., Fangzhou Suzhou. 
2015-2018, Postdoctoral fellow of The David Geffen School of Medicine at University of California--Los Angeles 

Academic title: 

Research areas: 

Study on the bionic drug carrier construction and application: cellular drug delivery, bio-based drug delivery, nano drug delivery for the treatment of central nervous system diseases, infectious diseases, etc.

1.Application of bionic drug carrier construction for central nervous system diseases

2.Engineering study of nebulized inhalation dosage forms

Honors and awards:

2020, National Natural Science Foundation of China for Youth Scholars, Host

2019, The National Key Research and Development Program of China, Backbone

2016, The 56th batch of China Postdoctoral Science Foundation.

Research projects: Synthetic biology and metabolic engineering of yeast S. cerevisiae for production of fuels, chemicals and natural products

Representative works:

[1] Meng Qin, Zheng Cao, Jing Wen, Qingsong Yu, Chaoyong Liu, Fang Wang, Fengmei Yang, Yanyan Li, Gregory Fishbein, Sen Yan, Bin Xu, Yi Hou, Zhenbo Ning, Kaili Nie, Ni Jiang, Zhen Liu, Jun Wu, Yanting Yu, Heng Li, Huiwen Zheng, Jing Li, Weihua Jin, Sheng Pan, Shuai Wang, Jian-feng Chen*, Zhihua Gan*, Zhanlong He* and ************. An Antioxidant Enzyme Therapeutic for COVID-19. Advanced Materials. 2020（202004901）

[2] Meng Qin, Lan Wang, Di Wu, Christopher K. Williams, Duo Xu, Emiko Kranz, Qi Guo, Jiaoqiong Guan, Harry V. Vinters, YooJin Lee, Yiming Xie, Yun Luo, Guibo Sun, Xiaobo Sun, Zhanlong He, ***********, Masakazu Kamata*, Jing Wen* and Irvin S. Y. Chen*. Enhanced Delivery of Rituximab into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates. Frontiers in Immunology 2019; 10.3132

[3] Di Wu, Meng Qin (Co-first author), Duo Xu, Chaoyong Liu, Jie Ren, Chen Chen, Fengmei Yang, Yanyan Li, Yuan Zhao, Ruyi Huang, Chunsheng Kang, Masakazu Kamata, Irvin S. Y. Chen, Zhanlong He*, Jing Wen*, Wei Chen*, and ************. A Bioinspired Platform for Effective Brain Delivery of Protein Therapeutics. Advanced Materials. 2019;31(18).

[4]Duo Xu, Di Wu, Meng Qin (Co-first author), Lina R. Nih, Chaoyong Liu, Jie Ren, Xiangjun Chen, Zhanlong He, Wenhai Yu, Jiaoqiong Guan, Suqin Duan, Fang Liu, Jesse Li, Dushawn Harley, Bin Xum, Irvin S.Y. Chen, Jing Wen*, Wei Chen*, Sina Pourtaheri*, and ************. Delivery of Neurotrophins to the Central Nervous System for Neural Regeneration. Advanced Materials. 2019; 31(33).

[5]Bolong Xu, Yan Cui, Weiwei Wang, Shanshan Li, Chengliang Lyu, Shuang Wang, Weier Bao, Hongyu Wang, Meng Qin, Zhen Liu, Wei Wei,* and Huiyu Liu* Immunomodulation-Enhanced Nanozyme-Based Tumor Catalytic Therapy. Advanced Materials. 202003563

[6] Jing Wen, Di Wu, Meng Qin, Chaoyong Liu, Duo Xu, Harry V. Vinters, Yang Liu, Emiko Kranz, YooJin Lee, Xin Guan, Guibo Sun, Xiaobo Sun, Otoniel Martinez-Maza, Daniel Widney, ***********, Irvin SY. Chen,* and Masakazu Kamata*. Delivering therapeutic mAb to control cancer with CNS metastases. Nature Biomedical Engineering, 2019.10.1038

[7]Lei Han, Chaoyong Liu, Hongzhao Qi, Junhu Zhou, Jing Wen, Di Wu, Duo Xu, Meng Qin, Jie Ren, Qixue Wang, Lixia Long, Yang Liu, Irvin Chen, Xubo Yuan,* ***********,* and Chunsheng Kang* Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy. Advanced Materials.2019, 201805697.

[8] Meng Qin, Xin Guan, Yu Zhang, Bin Shen, Fang Liu, Qingyu Zhang, Yupo Ma and Yongping Jiang*. Evaluation of ex vivo produced endothelial progenitor cells for autologous transplantation in primates. Stem Cell Research & Therapy (2018) 9:14

[9]Meng Qin, Xin Guan, Huihui Wang, Yu Zhang,Bin Shen, Qingyu Zhang, Wei Dai, Yupo Ma and Yongping Jiang*. An effective ex-vivo approach for inducing endothelial progenitor cells from umbilical cord blood CD34+ cells. Stem Cell Research & Therapy (2017) 8:25

[10]Meng Qin, Yun Luo, Shan Lu, Jing Sun, Ke Yang, Guibo Sun* and Xiaobo Sun*. Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling. Front Pharmacol. (2017) 22; 8: 953.

Admission requirements: